| 16.66 -1.32 (-7.34%) | 12-15 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 20.11 |
1-year : | 21.16 |
| Resists | First : | 17.21 |
Second : | 18.12 |
| Pivot price | 17.03  |
|||
| Supports | First : | 15.76 |
Second : | 13.11 |
| MAs | MA(5) : | 17.34 |
MA(20) : | 16.81 |
| MA(100) : | 14.39 |
MA(250) : | 0 | |
| MACD | MACD : | 0.5 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 73.5 |
D(3) : | 80 |
| RSI | RSI(14): 51.2 |
|||
| 52-week | High : | 18.12 | Low : | 7.5 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PHAR ] has closed above bottom band by 34.2%. Bollinger Bands are 21.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 17.81 - 17.9 | 17.9 - 17.96 |
| Low: | 16.44 - 16.56 | 16.56 - 16.63 |
| Close: | 16.5 - 16.67 | 16.67 - 16.78 |
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Mon, 15 Dec 2025
Pharming Group (NASDAQ:PHAR) Shares Gap Down - Here's What Happened - MarketBeat
Sat, 13 Dec 2025
(PHAR) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Sat, 13 Dec 2025
Pharming Group (NASDAQ:PHAR) Hits New 12-Month High - Should You Buy? - MarketBeat
Fri, 12 Dec 2025
Pharming Group NV stock hits 52-week high at 17.89 USD - Investing.com Nigeria
Mon, 08 Dec 2025
Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase - Should You Buy? - MarketBeat
Mon, 08 Dec 2025
Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 70 (M) |
| Shares Float | 492 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 14 (K) |
| Shares Short P.Month | 6 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.52 |
| Profit Margin | 0.1 % |
| Operating Margin | 26.6 % |
| Return on Assets (ttm) | 5.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 30 % |
| Gross Profit (p.s.) | 4.67 |
| Sales Per Share | 5.19 |
| EBITDA (p.s.) | 0.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 53 (M) |
| Levered Free Cash Flow | 44 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 31.43 |
| Price to Sales | 3.2 |
| Price to Cash Flow | 21.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|